Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ALZCUR.STthis companyAlzeCure Pharma AB	SEK 6.46	-4.26×	6.11×	0×	-3.24×	-92.8%	0.0%	0.0%	0.0%	-144.8%	-139.1%	-17.2%	0.16×	0.94×	-180.85×	2.33×	0.0%	5	15.15	3	B+
ACUC.STAcuCort AB	SEK 0.40	-2.73×	1.12×	103.97×	-1.68×	-33.7%	-2670.0%	-3856.3%	-3812.2%	-41.1%	-41.6%	-34.8%	0×	1.02×	-90.73×	8.08×	0.0%	3	9.81	1	C-
BOUL.STBoule Diagnostics AB	SEK 1.22	-49.1×	1.11×	0.38×	16.9×	-8578.3%	43.7%	0.9%	-0.8%	-2.3%	-0.7%	-2.2%	1.34×	8.83×	0.28×	1.09×	0.0%	3	0.3	2	C
ERMA.STEnorama Pharma AB (publ)	SEK 0.76	-1.77×	-5.66×	48.45×	-2.1×	-104.0%	-2255.6%	-2268.0%	-2743.3%	320.4%	264.9%	-44.7%	0×	0.05×	-4.91×	0.25×	0.0%	2	-29.47	2	C
IRLAB-A.STIRLAB Therapeutics AB (publ)	SEK 2.10	-1.2×	4.3×	2.3×	-0.91×	-160.0%	-160.7%	-160.7%	-191.4%	-358.1%	-152.2%	-41.8%	0.98×	0.59×	-5.13×	0.8×	0.0%	1	-3.89	2	C
KDEV.STKDventures AB	SEK 0.14	-0.61×	0.11×	10.89×	-0.49×	-1015.0%	90.8%	-1797.3%	-1794.8%	-18.6%	-18.4%	-22.2%	0×	0.12×	0×	24.45×	0.0%	3	-2.69	2	B-
Peer median	—	-1.77×	1.11×	10.89×	-0.91×	-160.0%	-160.7%	-1797.3%	-1794.8%	-18.6%	-18.4%	-34.8%	0×	0.59×	-4.91×	1.09×	0.0%	3	-2.69	2	—